Cullinan Therapeutics, Inc.
CGEM
$9.07
$0.111.23%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.98% | 27.12% | 10.97% | 7.87% | 2.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.26% | 3.29% | 4.22% | 11.27% | 5.13% |
| Operating Income | -22.26% | -3.29% | -4.22% | -11.27% | -5.13% |
| Income Before Tax | -20.35% | 1.04% | -0.71% | -7.85% | -218.14% |
| Income Tax Expenses | 100.83% | 100.83% | -660.06% | -222.35% | -122.89% |
| Earnings from Continuing Operations | -33.09% | -8.04% | 7.11% | -1.25% | -310.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -90.10% | 302.47% | 241.86% | 39.03% |
| Net Income | -35.05% | -9.28% | 8.07% | -0.28% | -302.52% |
| EBIT | -22.26% | -3.29% | -4.22% | -11.27% | -5.13% |
| EBITDA | -22.31% | -3.30% | -4.22% | -11.23% | -5.04% |
| EPS Basic | 1.51% | 15.34% | 22.90% | 7.74% | -333.93% |
| Normalized Basic EPS | 9.96% | 21.66% | 16.30% | 2.85% | -0.01% |
| EPS Diluted | 1.51% | 15.34% | 22.94% | 7.80% | -358.90% |
| Normalized Diluted EPS | 9.96% | 21.66% | 16.30% | 2.85% | -0.72% |
| Average Basic Shares Outstanding | 37.02% | 29.38% | 17.78% | 6.74% | -4.76% |
| Average Diluted Shares Outstanding | 37.02% | 29.38% | 17.78% | 6.74% | -5.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |